{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:58:23Z","timestamp":1794866303145,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn\u2019s disease (CD) and ulcerative colitis (UC) predisposes to IMC. In this study, we first develop a polygenic risk scores for CD (PRS\n                    <jats:sub>CD<\/jats:sub>\n                    ) and UC (PRS\n                    <jats:sub>UC<\/jats:sub>\n                    ) in cancer-free individuals and then test these PRSs on IMC in a cohort of 1316 patients with ICI-treated non-small cell lung cancer and perform a replication in 873 ICI-treated pan-cancer patients. In a meta-analysis, the PRS\n                    <jats:sub>UC<\/jats:sub>\n                    predicts all-grade IMC (OR\n                    <jats:sub>meta<\/jats:sub>\n                    =1.35 per standard deviation [SD], 95% CI\u2009=\u20091.12\u20131.64,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20092\u00d710\n                    <jats:sup>\u221203<\/jats:sup>\n                    ) and severe IMC (OR\n                    <jats:sub>meta<\/jats:sub>\n                    =1.49 per SD, 95% CI\u2009=\u20091.18\u20131.88,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20099\u00d710\n                    <jats:sup>\u221204<\/jats:sup>\n                    ). PRS\n                    <jats:sub>CD<\/jats:sub>\n                    is not associated with IMC. Furthermore, PRS\n                    <jats:sub>UC<\/jats:sub>\n                    predicts severe IMC among patients treated with combination ICIs (OR\n                    <jats:sub>meta<\/jats:sub>\n                    =2.20 per SD, 95% CI\u2009=\u20091.07\u20134.53,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.03). Overall,\u00a0PRS\n                    <jats:sub>UC<\/jats:sub>\n                    can identify patients receiving ICI at risk of developing IMC and may be useful to monitor patients and improve patient outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-44512-4","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T07:02:02Z","timestamp":1711436522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-8215","authenticated-orcid":false,"given":"Pooja","family":"Middha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Thummalapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-6202","authenticated-orcid":false,"given":"Michael J.","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Quandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmugi","family":"Balaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-0584","authenticated-orcid":false,"given":"Cosmin A.","family":"Bejan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina J.","family":"Falcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Faleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Princess Margaret Lung Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope A.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Gubens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Huntsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-773X","authenticated-orcid":false,"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-4727","authenticated-orcid":false,"given":"Linda","family":"Kachuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaleeq","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-6361","authenticated-orcid":false,"given":"Christine M.","family":"Lovly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-2626","authenticated-orcid":false,"given":"Megan H.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devalben","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Werking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna Jia","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-5974","authenticated-orcid":false,"given":"Justin M.","family":"Balko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-8448","authenticated-orcid":false,"given":"Melinda C.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2644-1416","authenticated-orcid":false,"given":"Adam J.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-2884","authenticated-orcid":false,"given":"Elad","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"44512_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1097\/CM9.0000000000001490","volume":"134","author":"RL Bai","year":"2021","unstructured":"Bai, R. L., Chen, N. F., Li, L. Y. & Cui, J. W. A brand new era of cancer immunotherapy: breakthroughs and challenges. Chin. Med. J. (Engl.). 134, 1267\u20131275 (2021).","journal-title":"Chin. Med. J. (Engl.)."},{"key":"44512_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"44512_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey, J. D. & Zhang, B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 23, 39 (2021).","journal-title":"AAPS J."},{"key":"44512_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 27, 450\u2013461 (2015).","journal-title":"Cancer Cell."},{"key":"44512_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12531","volume":"276","author":"AH Sharpe","year":"2017","unstructured":"Sharpe, A. H. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol. Rev. 276, 5\u20138 (2017).","journal-title":"Immunol. Rev."},{"key":"44512_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).","journal-title":"Nat. Commun."},{"key":"44512_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"key":"44512_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98\u2013106 (2016).","journal-title":"Am. J. Clin. Oncol."},{"key":"44512_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"44512_CR10","doi-asserted-by":"publisher","first-page":"e001460","DOI":"10.1136\/jitc-2020-001460","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu, X., Hogg, G. D. & DeNardo, D. G. Rethinking immune checkpoint blockade: \u2018Beyond the T cell. J. Immunother. Cancer 9, e001460 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"44512_CR11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMe1205943","volume":"366","author":"A Ribas","year":"2012","unstructured":"Ribas, A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517\u20132519 (2012).","journal-title":"N. Engl. J. Med."},{"key":"44512_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun, D. J., Wolchok, J. D., Rosenberg, L. M. & Girotra, M. Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13, 195\u2013207 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"44512_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"44512_CR14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials. JAMA Oncol. 5, 1008\u20131019 (2019).","journal-title":"JAMA Oncol."},{"key":"44512_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","volume":"71","author":"N Okiyama","year":"2022","unstructured":"Okiyama, N. & Tanaka, R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol. Int. 71, 169\u2013178 (2022).","journal-title":"Allergol. Int."},{"key":"44512_CR16","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"Shankar, B. et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 6, 1952\u20131956 (2020).","journal-title":"JAMA Oncol."},{"key":"44512_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy, M. & Naidoo, J. Immune-related adverse events and the balancing act of immunotherapy. Nat. Commun. 13, 392 (2022).","journal-title":"Nat. Commun."},{"key":"44512_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","volume":"7","author":"A Som","year":"2019","unstructured":"Som, A. et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J. Clin. Cases 7, 405\u2013418 (2019).","journal-title":"World J. Clin. Cases"},{"key":"44512_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.crohns.2013.09.019","volume":"8","author":"C Pocha","year":"2014","unstructured":"Pocha, C., Roat, J. & Viskocil, K. Immune-mediated colitis: important to recognize and treat. J. Crohn\u2019s Colitis 8, 181\u2013182 (2014).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"44512_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H. & Sharpe, A. H. Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol. 40, 511\u2013523 (2019).","journal-title":"Trends Immunol."},{"key":"44512_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11894-022-00852-7","volume":"24","author":"MR Kelly-Goss","year":"2022","unstructured":"Kelly-Goss, M. R., Badran, Y. R. & Dougan, M. Update on immune checkpoint inhibitor Enterocolitis. Curr. Gastroenterol. Rep. 24, 171\u2013181 (2022).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"44512_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","volume":"41","author":"JH Chen","year":"2017","unstructured":"Chen, J. H., Pezhouh, M. K., Lauwers, G. Y. & Masia, R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am. J. Surg. Pathol. 41, 643\u2013654 (2017).","journal-title":"Am. J. Surg. Pathol."},{"key":"44512_CR23","doi-asserted-by":"publisher","first-page":"e001488","DOI":"10.1136\/jitc-2020-001488","volume":"8","author":"KJ Nahar","year":"2020","unstructured":"Nahar, K. J. et al. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. J. Immunother. Cancer 8, e001488 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"44512_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/clpt.2008.89","volume":"84","author":"DM Roden","year":"2008","unstructured":"Roden, D. M. et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharm. Ther. 84, 362\u2013369 (2008).","journal-title":"Clin. Pharm. Ther."},{"key":"44512_CR25","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1093\/bioinformatics\/btaa1029","volume":"36","author":"F Priv\u00e9","year":"2020","unstructured":"Priv\u00e9, F., Arbel, J. & Vilhj\u00e1lmsson, B. J. LDpred2: better, faster, stronger. Bioinformatics 36, 5424\u20135431 (2020).","journal-title":"Bioinformatics"},{"key":"44512_CR26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/apt.15485","volume":"50","author":"JJ Ashton","year":"2019","unstructured":"Ashton, J. J., Latham, K., Beattie, R. M. & Ennis, S. Review article: the genetics of the human leucocyte antigen region in inflammatory bowel disease. Aliment. Pharmacol. Ther. 50, 885\u2013900 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"44512_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/ng.3176","volume":"47","author":"P Goyette","year":"2015","unstructured":"Goyette, P. et al. High density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat. Genet. 47, 172\u2013179 (2015).","journal-title":"Nat. Genet."},{"key":"44512_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo, J. A., Kimbrough, E. O. & Lou, Y. Next generation of immune checkpoint inhibitors and beyond. J. Hematol. Oncol. 14, 45 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"44512_CR29","doi-asserted-by":"publisher","first-page":"1063183","DOI":"10.3389\/fonc.2023.1063183","volume":"13","author":"WF Tang","year":"2023","unstructured":"Tang, W. F. et al. Adjuvant immunotherapy in early-stage resectable non\u2013small cell lung cancer: a new milestone. Front. Oncol. 13, 1063183 (2023).","journal-title":"Front. Oncol."},{"key":"44512_CR30","doi-asserted-by":"publisher","unstructured":"Mittendorf, E. A., Burgers, F., Haanen, J. & Cascone, T. Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease. Am. Soc. Clin. Oncol. Educ. Book. 189\u2013203 https:\/\/doi.org\/10.1200\/EDBK_349411 (2022)","DOI":"10.1200\/EDBK_349411"},{"key":"44512_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/jnci\/djaa216","volume":"113","author":"M Krishnamoorthy","year":"2021","unstructured":"Krishnamoorthy, M., Lenehan, J. G. & Maleki Vareki, S. Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges. J. Natl Cancer Inst. 113, 823\u2013832 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"44512_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fchem.2020.00601","volume":"8","author":"HG Hu","year":"2020","unstructured":"Hu, H. G. & Li, Y. M. Emerging adjuvants for cancer immunotherapy. Front. Chem. 8, 601 (2020).","journal-title":"Front. Chem."},{"key":"44512_CR33","doi-asserted-by":"publisher","first-page":"2018894","DOI":"10.1080\/21645515.2021.2018894","volume":"18","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. Hum. Vaccin. Immunother. 18, 2018894 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"44512_CR34","doi-asserted-by":"publisher","first-page":"585311","DOI":"10.3389\/fonc.2020.585311","volume":"10","author":"JW Hommes","year":"2021","unstructured":"Hommes, J. W., Verheijden, R. J., Suijkerbuijk, K. P. M. & Hamann, D. Biomarkers of checkpoint inhibitor induced immune-related adverse events\u2014a comprehensive review. Front Oncol. 10, 585311 (2021).","journal-title":"Front Oncol."},{"key":"44512_CR35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/OP.20.00620","volume":"16","author":"LC Kennedy","year":"2020","unstructured":"Kennedy, L. C. & Grivas, P. Immunotherapy-related colitis: an emerging challenge and a quest for prospective data. JCO Oncol. Pract. 16, 464\u2013465 (2020).","journal-title":"JCO Oncol. Pract."},{"key":"44512_CR36","doi-asserted-by":"crossref","unstructured":"Westdorp, H. et al. Mechanisms of immune checkpoint inhibitor-mediated colitis. Front. Immunol. 2021;12. Accessed September 23, 2022. https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.768957.","DOI":"10.3389\/fimmu.2021.768957"},{"key":"44512_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ng.3761","volume":"49","author":"Y Luo","year":"2017","unstructured":"Luo, Y. et al. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nat. Genet. 49, 186\u2013192 (2017).","journal-title":"Nat. Genet."},{"key":"44512_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/ecco-jcc\/jjx157","volume":"12","author":"A Onoufriadis","year":"2018","unstructured":"Onoufriadis, A. et al. Exome sequencing and genotyping identify a rare variant in NLRP7 gene associated with ulcerative colitis. J. Crohn\u2019s Colitis 12, 321\u2013326 (2018).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"44512_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/00365521.2014.990507","volume":"50","author":"D Ellinghaus","year":"2015","unstructured":"Ellinghaus, D., Bethune, J., Petersen, B. S. & Franke, A. The genetics of Crohn\u2019s disease and ulcerative colitis\u2013status quo and beyond. Scand. J. Gastroenterol. 50, 13\u201323 (2015).","journal-title":"Scand. J. Gastroenterol."},{"key":"44512_CR40","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-21-0921","volume":"27","author":"J Luo","year":"2021","unstructured":"Luo, J. et al. Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non\u2013small cell lung cancer. Clin. Cancer Res. 27, 5131\u20135140 (2021).","journal-title":"Clin. Cancer Res."},{"key":"44512_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23661-4","volume":"12","author":"Z Khan","year":"2021","unstructured":"Khan, Z. et al. Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nat. Commun. 12, 3355 (2021).","journal-title":"Nat. Commun."},{"key":"44512_CR42","doi-asserted-by":"publisher","first-page":"12288","DOI":"10.1073\/pnas.1922867117","volume":"117","author":"Z Khan","year":"2020","unstructured":"Khan, Z. et al. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. Proc. Natl Acad. Sci. USA 117, 12288\u201312294 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"44512_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou, X. et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 18, 87 (2020).","journal-title":"BMC Med."},{"key":"44512_CR44","doi-asserted-by":"crossref","unstructured":"Zhao, Z. et al. Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 inhibitors: a systematic review and meta-analysis. Front. Oncol. 2021;11. Accessed June 1, 2022. https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2021.708195.","DOI":"10.3389\/fonc.2021.708195"},{"key":"44512_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","volume":"43","author":"F Petrelli","year":"2020","unstructured":"Petrelli, F. et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J. Immunother. 43, 1\u20137 (2020).","journal-title":"J. Immunother."},{"key":"44512_CR46","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","volume":"23","author":"Y Toi","year":"2018","unstructured":"Toi, Y. et al. Association of immune\u2010related adverse events with clinical benefit in patients with advanced non\u2010small\u2010cell lung cancer treated with nivolumab. Oncologist 23, 1358\u20131365 (2018).","journal-title":"Oncologist"},{"key":"44512_CR47","doi-asserted-by":"publisher","first-page":"630136","DOI":"10.3389\/fonc.2021.630136","volume":"11","author":"K Morimoto","year":"2021","unstructured":"Morimoto, K. et al. Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy: a retrospective study. Front. Oncol. 11, 630136 (2021).","journal-title":"Front. Oncol."},{"key":"44512_CR48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","volume":"68","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih, H. et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol. Immunother. 68, 553\u2013561 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"44512_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0461-4","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih, H. et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor\u2013induced colitis: a multi-center study. J. Immunother. Cancer 6, 142 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"44512_CR50","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","volume":"66","author":"V Bergqvist","year":"2017","unstructured":"Bergqvist, V. et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol. Immunother. 66, 581\u2013592 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"44512_CR51","doi-asserted-by":"crossref","unstructured":"Park, R., Lopes, L., Cristancho, C. R., Riano, I. M. & Saeed, A. Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis. Front. Oncol. 2020;10. Accessed March 15, 2023. https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.00258.","DOI":"10.3389\/fonc.2020.00258"},{"key":"44512_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares, L. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 198\u2013211 (2021).","journal-title":"Lancet Oncol."},{"key":"44512_CR53","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","volume":"10","author":"L Da","year":"2020","unstructured":"Da, L. et al. Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials. Front. Pharmacol. 10, 1671 (2020).","journal-title":"Front. Pharmacol."},{"key":"44512_CR54","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.18632\/oncotarget.26908","volume":"10","author":"A Carretero-Gonz\u00e1lez","year":"2019","unstructured":"Carretero-Gonz\u00e1lez, A. et al. Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials. Oncotarget 10, 3294\u20133301 (2019).","journal-title":"Oncotarget"},{"key":"44512_CR55","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/ajco.13365","volume":"16","author":"M Zhuo","year":"2020","unstructured":"Zhuo, M., Chi, Y. & Wang, Z. The adverse events associated with combination immunotherapy in cancers: Challenges and chances. Asia-Pac. J. Clin. Oncol. 16, e154\u2013e159 (2020).","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"44512_CR56","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398, 1344\u20131357 (2021).","journal-title":"Lancet"},{"key":"44512_CR57","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien, M. et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 23, 1274\u20131286 (2022).","journal-title":"Lancet Oncol."},{"key":"44512_CR58","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke, J. J. et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 399, 1718\u20131729 (2022).","journal-title":"Lancet"},{"key":"44512_CR59","doi-asserted-by":"publisher","first-page":"910","DOI":"10.21037\/tlcr-21-698","volume":"11","author":"RJ Klein","year":"2022","unstructured":"Klein, R. J. & G\u00fcm\u00fc\u015f, Z. H. Are polygenic risk scores ready for the cancer clinic?-a perspective. Transl. Lung Cancer Res. 11, 910\u2013919 (2022).","journal-title":"Transl. Lung Cancer Res."},{"key":"44512_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00829-7","volume":"13","author":"ACF Lewis","year":"2021","unstructured":"Lewis, A. C. F. & Green, R. C. Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Med. 13, 14 (2021).","journal-title":"Genome Med."},{"key":"44512_CR61","first-page":"100047","volume":"2","author":"ACF Lewis","year":"2021","unstructured":"Lewis, A. C. F., Green, R. C. & Vassy, J. L. Polygenic risk scores in the clinic: translating risk into action. HGG Adv. 2, 100047 (2021).","journal-title":"HGG Adv."},{"key":"44512_CR62","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","volume":"51","author":"AR Martin","year":"2019","unstructured":"Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584\u2013591 (2019).","journal-title":"Nat. Genet."},{"key":"44512_CR63","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1053\/j.gastro.2020.09.056","volume":"160","author":"M Lee","year":"2021","unstructured":"Lee, M. & Chang, E. B. Inflammatory bowel diseases (IBD) and the microbiome\u2014searching the crime scene for clues. Gastroenterology 160, 524\u2013537 (2021).","journal-title":"Gastroenterology"},{"key":"44512_CR64","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson, J. R., Cain, K. C. & Gelber, R. D. Analysis of survival by tumor response. J. Clin. Oncol. 1, 710\u2013719 (1983).","journal-title":"J. Clin. Oncol."},{"key":"44512_CR65","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","volume":"26","author":"JR Anderson","year":"2008","unstructured":"Anderson, J. R., Cain, K. C. & Gelber, R. D. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J. Clin. Oncol. 26, 3913\u20133915 (2008).","journal-title":"J. Clin. Oncol."},{"key":"44512_CR66","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","volume":"26","author":"CJ Morgan","year":"2019","unstructured":"Morgan, C. J. Landmark analysis: a primer. J. Nucl. Cardiol. 26, 391\u2013393 (2019).","journal-title":"J. Nucl. Cardiol."},{"key":"44512_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203\u2013209 (2018).","journal-title":"Nature"},{"key":"44512_CR68","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ng.3760","volume":"49","author":"KM de Lange","year":"2017","unstructured":"de Lange, K. M. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256\u2013261 (2017).","journal-title":"Nat. Genet."},{"key":"44512_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21541-5","volume":"12","author":"S Cook","year":"2021","unstructured":"Cook, S. et al. Accurate imputation of human leukocyte antigens with CookHLA. Nat. Commun. 12, 1264 (2021).","journal-title":"Nat. Commun."},{"key":"44512_CR70","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/bioinformatics\/btaa684","volume":"37","author":"W Choi","year":"2021","unstructured":"Choi, W., Luo, Y., Raychaudhuri, S. & Han, B. HATK: HLA analysis toolkit. Bioinformatics 37, 416\u2013418 (2021).","journal-title":"Bioinformatics"},{"key":"44512_CR71","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1463-1326.2008.00997.x","volume":"11","author":"WM Brown","year":"2009","unstructured":"Brown, W. M. et al. Overview of the MHC fine mapping data. Diabetes Obes. Metab. 11, 2\u20137 (2009) .","journal-title":"Diabetes Obes. Metab."},{"key":"44512_CR72","doi-asserted-by":"publisher","unstructured":"Middha, P. PoojaMiddha\/GeRI_colitis: Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. Published online November 20, 2023. https:\/\/doi.org\/10.5281\/ZENODO.10162343.","DOI":"10.5281\/ZENODO.10162343"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44512-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T07:03:06Z","timestamp":1711436586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44512-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["44512"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-44512-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.05.15.23289680","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.B. receives research support from Genentech\/Roche and Incyte Corporation, has received advisory board payments from AstraZeneca and Mallinckrodt, and is an inventor on patents regarding immunotherapy targets and biomarkers in cancer. The remaining authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2568"}}